Medincell Sa Stock Performance
| MDCLF Stock | USD 14.00 7.02 100.57% |
On a scale of 0 to 100, MedinCell holds a performance score of 4. The company secures a Beta (Market Risk) of 0.3, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, MedinCell's returns are expected to increase less than the market. However, during the bear market, the loss of holding MedinCell is expected to be smaller as well. Please check MedinCell's variance, daily balance of power, period momentum indicator, as well as the relationship between the total risk alpha and day typical price , to make a quick decision on whether MedinCell's current price movements will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in MedinCell SA are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain essential indicators, MedinCell reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 47.1 M | |
| Total Cashflows From Investing Activities | -316 K |
MedinCell |
MedinCell Relative Risk vs. Return Landscape
If you would invest 698.00 in MedinCell SA on September 25, 2024 and sell it today you would earn a total of 0.00 from holding MedinCell SA or generate 0.0% return on investment over 90 days. MedinCell SA is currently producing 0.8005% returns and takes up 14.2494% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than MedinCell, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
MedinCell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MedinCell's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as MedinCell SA, and traders can use it to determine the average amount a MedinCell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0562
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MDCLF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 14.25 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.8 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average MedinCell is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MedinCell by adding it to a well-diversified portfolio.
MedinCell Fundamentals Growth
MedinCell Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of MedinCell, and MedinCell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MedinCell Pink Sheet performance.
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 190.33 M | |||
| Shares Outstanding | 25.22 M | |||
| Price To Book | 34.52 X | |||
| Price To Sales | 31.58 X | |||
| Revenue | 4.09 M | |||
| EBITDA | (21.45 M) | |||
| Cash And Equivalents | 34.39 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 4.86 % | |||
| Book Value Per Share | (1.04) X | |||
| Cash Flow From Operations | (21.36 M) | |||
| Earnings Per Share | (0.88) X | |||
| Total Asset | 44.3 M | |||
About MedinCell Performance
By analyzing MedinCell's fundamental ratios, stakeholders can gain valuable insights into MedinCell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MedinCell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MedinCell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. Medincell is traded on OTC Exchange in the United States.Things to note about MedinCell SA performance evaluation
Checking the ongoing alerts about MedinCell for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for MedinCell SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MedinCell SA is way too risky over 90 days horizon | |
| MedinCell SA appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 4.09 M. Net Loss for the year was (24.81 M) with profit before overhead, payroll, taxes, and interest of 4.09 M. | |
| MedinCell SA has accumulated about 34.39 M in cash with (21.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. | |
| Roughly 48.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing MedinCell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MedinCell's stock is overvalued or undervalued compared to its peers.
- Examining MedinCell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MedinCell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MedinCell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MedinCell's pink sheet. These opinions can provide insight into MedinCell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MedinCell Pink Sheet analysis
When running MedinCell's price analysis, check to measure MedinCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedinCell is operating at the current time. Most of MedinCell's value examination focuses on studying past and present price action to predict the probability of MedinCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedinCell's price. Additionally, you may evaluate how the addition of MedinCell to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |